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bAbout 8 years ago, a small group of individuals
aised the notion of establishing a clinical trials net-
ork that would be dedicated to addressing, prospec-
ively, the key clinical issues in blood and marrow
ransplantation. The enterprise would be funded
ointly by the National Heart, Lung and Blood Insti-
ute (NHLBI) and the National Cancer Institute
NCI) with important input from two existing clinical
one and marrow transplant (BMT) networks, the
ational Marrow Donor Program (NMDP) and the
nternational Blood and Marrow Transplant Registry
IBMTR)/Autologous Blood and Marrow Transplant
egistry (ABMTR) (now afﬁliated as the Center for
nternational Blood and Marrow Transplant Research
CIBMTR). Although a controversial idea then, the
lood and Marrow Transplant Clinical Trials Net-
ork (BMT CTN) was nevertheless born in 2001 in
uch the way that it had been proposed. At the time,
ome in our community argued that it was unneces-
ary because cancer cooperative groups had addressed
uccessfully some of the important issues in BMT and
ould continue to do so, that federal funds would be
iverted from individual centers with a track record of
ackling clinical BMT issues in an innovative way, and
hat many, especially smaller BMT centers, would be
xcluded from participation. Other no less compelling
rguments were also raised.
It is particularly heartening, therefore, that the
rticle by Weisdorf et al of this issue of BBMT dispels
irtually all of those concerns and provides an update
n how this venture has progressed. Indeed, the BMT
TN can claim remarkable success: total accrual to
rospective clinical trials now exceeds 1400 patients
ince the Network was established. The studies span fhe gamut of issues in BMT and include comparisons
f graft sources, approaches to reducing regimen-
elated toxicity, optimum management of graft-ver-
us-host disease, and assessment of late effects and
uality of life, to name only some that are underway.
It is noteworthy that at least one trial is in collab-
ration with a cooperative oncology group (in this
ase Cancer and Leukemia Group B (CALGB), an
pproach that strengthens both organizations and
rovides a complementary model to address trans-
lant- and disease-related issues simultaneously. The
MT CTN is especially constituted to address trans-
lant-speciﬁc issues and, as Weisdorf and colleagues
oint out, has embarked on a number of ambitious
tudies, including the comparison of bone marrow
ersus ﬁlgrastim mobilized peripheral blood cells for
nrelated donor hematopoietic cell transplantation, an
mportant randomized trial that would be difﬁcult to
onduct by any other group and certainly not as
uickly. An expected strength of the Network would
e the adequate accrual to trials involving rare dis-
ases; hence, a study is underway to investigate re-
uced transplant-related toxicity in patients with
plastic anemia. Opportunities also appear to be avail-
ble for the Network to evaluate phase II data from
ingle centers as the basis for Network-sponsored pro-
pective phase III trials. This may be a particularly
ppealing vehicle for large centers to have their inno-
ative ideas evaluated prospectively.
Weisdorf et al also outline the organizational
tructure of the CTN. Sixteen core centers and 50
oncore centers participate in the Network. It is run
y a Steering Committee that includes representatives
rom the core centers, the funding agencies, and oth-
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A. Keating256rs. Given the structure of the Network, it appears
hat most centers have adequate access and are able to
articipate in Network-sponsored trials.
The BMT CTN is still a young organization. Its
hallenges include how to optimize interactions with
ooperative cancer groups, how to invite the partici-
ation of centers outside the designated 50 noncore
enters that nonetheless can contribute patients and
deas, how to incorporate key translational studies in
he CTN protocols, and ultimately, with the limited Cesources available, how to identify the studies that
ill move the ﬁeld forward substantively. For exam-
le, it is beautifully placed to conduct molecular epi-
emiology studies (using patient and donor tissue),
hich may provide profound insights into how best to
anage patients with BMT. This will require addi-
ional resources and expertise, but given the foresight
f its founders, there is cause for considerable opti-
ism that much will be accomplished by the BMT
TN.
